Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;47(10):1194-9.
doi: 10.1038/ng.3382. Epub 2015 Sep 7.

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

A Hunter Shain  1   2   3 , Maria Garrido  1   2   3 , Thomas Botton  1   2   3 , Eric Talevich  1   2   3 , Iwei Yeh  1   2   3 , J Zachary Sanborn  4 , Jongsuk Chung  5 , Nicholas J Wang  6   7 , Hojabr Kakavand  8   9 , Graham J Mann  8   9 , John F Thompson  8   9   10 , Thomas Wiesner  11 , Ritu Roy  2 , Adam B Olshen  2   12 , Alexander Gagnon  1   2   3 , Joe W Gray  6   7 , Nam Huh  5 , Joe S Hur  13 , Klaus J Busam  14 , Richard A Scolyer  8   9   10 , Raymond J Cho  3 , Rajmohan Murali  14   15 , Boris C Bastian  1   2   3
Affiliations

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

A Hunter Shain et al. Nat Genet. 2015 Oct.

Abstract

Desmoplastic melanoma is an uncommon variant of melanoma with sarcomatous histology, distinct clinical behavior and unknown pathogenesis. We performed low-coverage genome and high-coverage exome sequencing of 20 desmoplastic melanomas, followed by targeted sequencing of 293 genes in a validation cohort of 42 cases. A high mutation burden (median of 62 mutations/Mb) ranked desmoplastic melanoma among the most highly mutated cancers. Mutation patterns strongly implicate ultraviolet radiation as the dominant mutagen, indicating a superficially located cell of origin. Newly identified alterations included recurrent promoter mutations of NFKBIE, encoding NF-κB inhibitor ɛ (IκBɛ), in 14.5% of samples. Common oncogenic mutations in melanomas, in particular in BRAF (encoding p.Val600Glu) and NRAS (encoding p.Gln61Lys or p.Gln61Arg), were absent. Instead, other genetic alterations known to activate the MAPK and PI3K signaling cascades were identified in 73% of samples, affecting NF1, CBL, ERBB2, MAP2K1, MAP3K1, BRAF, EGFR, PTPN11, MET, RAC1, SOS2, NRAS and PIK3CA, some of which are candidates for targeted therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Desmoplastic melanomas have a substantial point mutation burden consistent with UV-radiation induced damage
The 62 tumors are ordered by their mutation burden (top panel) with the mutation types annotated (bottom panel). Dashed line corresponds to the mutation burden observed in sun-exposed non-desmoplastic melanoma: 15 mutations/Mb,. In the bottom panel, C>T mutations following a purine (*) or a pyrimidine (**) are distinguished. Tumors from patients older than 55 years of age had significantly more mutations as compared to those from younger patients (p=2×10-3, t-test). Cases from the discovery cohort are marked with a “D”.
Figure 2
Figure 2. Nomination of driver mutations in desmoplastic melanoma
A. The number of specific mutations detected (y-axis) is stratified by those mutations' occurrences across samples (x-axis). For example, 3,364 mutations occurred only once, whereas there were 151 mutations occurring in two samples and a single mutation was observed 9 times, affecting the NFKBIE genetic locus. There was also a secondary hotspot in NFKBIE, 15 basepairs from the more common mutation site, which was mutated in two samples. B. Q-Q plot of loss-of-function burdens compared to expected loss-of-function burdens, calculated as described. Solid and dotted lines correspond to false discovery rates (FDRs) of 1.0 and 0.5, respectively. The most significant genes are labeled. C. Tumor suppressor candidates have an increased proportion of damaging mutations and fully clonal mutant allele frequencies (MAFs), undergoing loss of heterozygosity in some cases. Left panel: Fraction of mutation categories compared to all mutations. Right panel: Normalized MAFs (calculated as described) of candidate mutations compared to all mutations. Red vertical bars indicate average MAFs.
Figure 3
Figure 3. Genetic alterations of CBL, MAP3K1, FBXW7, and NFKBIE
A. Enrichment of damaging mutations of CBL in desmoplastic melanoma. B. Recurrent amplification of MAP3K1. C. Enrichment of damaging mutations of FBXW7 in desmoplastic melanoma. D. Recurrent amplification of NFKBIE.
Figure 4
Figure 4. Recurrent mutations affect the promoter of NFKBIE
Mutations are annotated over the entire NFKBIE genetic locus (top panel) and a zoomed inset (bottom panel) with selected tracks featured as described in the main text.
Figure 5
Figure 5. The mutational landscape of desmoplastic melanoma
A. Tiling plot of genetic alterations (rows) in each sample (columns). Mutations were considered homozygous if their MAFs were 1.5× the sample median. Numbers indicate the percent of samples harboring oncogenic alterations. Purple (*) tiles indicate unique hotspot mutations as discussed. GOF = gain-of-function. B. Pathways affected.
See this image and copyright information in PMC

Comment in

  • Desmoplastic melanoma: C>Ts and NF-κB.
    Rabbie R, Adams DJ. Rabbie R, et al. Pigment Cell Melanoma Res. 2016 Mar;29(2):120-1. doi: 10.1111/pcmr.12451. Epub 2016 Jan 20. Pigment Cell Melanoma Res. 2016. PMID: 26663830 Free PMC article. No abstract available.

Similar articles

See all similar articles

Cited by

  • Evolving treatments and future therapeutic targets in desmoplastic melanoma.
    Hadfield MJ, Turshudzhyan A, Grant-Kels JM. Hadfield MJ, et al. Melanoma Manag. 2021 Jun 17;8(3):MMT56. doi: 10.2217/mmt-2020-0013. eCollection 2021 Sep. Melanoma Manag. 2021. PMID: 34900219 Free PMC article. No abstract available.
  • Clinical characteristics of malignant melanoma in central China and predictors of metastasis.
    Shi K, Zhu X, Liu Z, Sun N, Gu L, Wei Y, Cheng X, Zhang Z, Xie B, Yang S, Li G, Liu L. Shi K, et al. Oncol Lett. 2020 Feb;19(2):1452-1464. doi: 10.3892/ol.2019.11219. Epub 2019 Dec 16. Oncol Lett. 2020. PMID: 32002034 Free PMC article.
  • Whole-genome landscapes of major melanoma subtypes.
    Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ. Hayward NK, et al. Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3. Nature. 2017. PMID: 28467829
  • Distinguishing Neurofibroma From Desmoplastic Melanoma: The Value of p53.
    Elsensohn A, Shiu J, Grove N, Hosking AM, Barr R, de Feraudy S. Elsensohn A, et al. Am J Surg Pathol. 2018 Mar;42(3):372-375. doi: 10.1097/PAS.0000000000000978. Am J Surg Pathol. 2018. PMID: 29112020 Free PMC article.
  • zDHHC-Mediated S-Palmitoylation in Skin Health and Its Targeting as a Treatment Perspective.
    Abdulrahman FA, Benford KA, Lin GT, Maroun AJ, Sammons C, Shirzad DN, Tsai H, Van Brunt VL, Jones Z, Marquez JE, Ratkus EC, Shehadeh AK, Abasto Valle H, Fejzo D, Gilbert AE, McWee CA, Underwood LF, Indico E, Rork BB, Nanjundan M. Abdulrahman FA, et al. Int J Mol Sci. 2025 Feb 15;26(4):1673. doi: 10.3390/ijms26041673. Int J Mol Sci. 2025. PMID: 40004137 Free PMC article. Review.
See all "Cited by" articles

References

    1. Quinn MJ, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer. 1998;83:1128–1135. - PubMed
    1. Chen LL, Jaimes N, Barker CA, Busam KJ, Marghoob AA. Desmoplastic melanoma: a review. J Am Acad Dermatol. 2013;68:825–833. - PMC - PubMed
    1. Wasif N, Gray RJ, Pockaj BA. Desmoplastic melanoma - the step-child in the melanoma family? J Surg Oncol. 2011;103:158–162. - PubMed
    1. Vogelstein B, et al. Cancer Genome Landscapes. Science. 2013;339:1546–1558. - PMC - PubMed
    1. Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013 doi: 10.1038/nature12477. - DOI - PMC - PubMed

Publication types